Biosimilars: Breaking Down Barriers to Patient Access (REMS) | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks with Mary Beth Powers, President and CEO of CMMB.

Biosimilars: Breaking Down Barriers to Patient Access (REMS)

Since it was created in 2007, the Food & Drug Administration’s (FDA’s) Risk Evaluation and Mitigation Strategies (REMS) has been an important tool for patient safety by ensuring that the benefits of a drug or biological product outweigh its safety risks. FDA-mandated REMS serve a clear public health purpose, yet some brand drug companies have been misusing this patient safety program and other restricted access drug programs to extend market monopolies, intentionally limiting patient access to biosimilars. These abuses are growing, resulting in delayed approval of biosimilars, costing patients, the federal government and the health care system billions of dollars.

Biosimilars - Breaking Down Barriers to Patient Access

REMS Infographic -  Biosimilars

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.